RoTecPSMA® Approved in Switzerland – Expanding Access to Advanced Prostate Cancer Diagnostics
We are delighted to announce that RoTecPSMA® has received marketing authorization in Switzerland, marking another important milestone in the European rollout of this innovative diagnostic solution. This approval, achieved in close collaboration with our trusted partner and marketing authorization holder medeo AG, paves the way for Swiss patients to benefit from our PSMA SPECT tracer.
RoTecPSMA® is a technetium-99m cold kit for SPECT imaging of prostate cancer patients and represents the first PSMA SPECT tracer approved in a European country. With its authorization, we continue to address critical gaps in patient care by offering a widely accessible and reliable diagnostic radiopharmaceutical.
This milestone reflects our strong commitment to enhancing diagnostic precision and improving quality of life for patients through theranostics. By expanding access to advanced diagnostic imaging solutions, we aim to ensure that more men living with prostate cancer can receive timely and precise assessments, ultimately enabling more informed and effective treatment decisions.
With approval granted, we are now moving forward with medeo AG to prepare for the market launch of RoTecPSMA® in Switzerland. While some steps are still required, we are progressing toward making RoTecPSMA® available to Swiss healthcare providers. Based on current planning, we anticipate broad availability could begin in the second quarter of 2026.
The Swiss approval also highlights the importance of strategic partnerships. Our collaboration with medeo AG ensures not only efficient distribution but also the local expertise required to successfully integrate RoTecPSMA® into the Swiss healthcare system, providing physicians with a powerful tool in the fight against prostate cancer.
We look forward to seeing the positive impact RoTecPSMA® will have on patient care in Switzerland and to continuing our mission of bringing innovative nuclear medicine solutions to healthcare professionals and patients worldwide.
Fore more information contact our Customer Service Team: customer.service@rotop-pharmaka.com
Ähnliche Beiträge
Saxon State Parliament member Thomas Schmidt visits ROTOP
August 7, 2026 - A reunion with a long-standing companion: Saxon State Parliament member Thomas Schmidt visited our Radiopharmacy to learn about its development since its inauguration in 2020. The discussions focused on the future of radiopharmacy and nuclear medicine as well as the European framework for innovative diagnostic and therapeutic approaches.
ROTOP Receives Building Permit for New Radiopharmaceutical Manufacturing Facility in Dresden
April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.
New CFO at ROTOP – Dr. Michael Peterseim
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
